Exenatide Reference

Plain English

What it is

Exenatide is a man-made medicine in the GLP-1 group (short for glucagon-like peptide-1 receptor agonists), a family of blood-sugar drugs. It is one of the earliest GLP-1 medicines, first approved by the US Food and Drug Administration (FDA) in 2005, and has been sold under the brand names Byetta, Bydureon, and Bydureon BCise.

What people use it for

It is approved to help adults with type 2 diabetes control their blood sugar, used together with a healthy diet and exercise. It is a diabetes medicine and is not approved for weight loss; many people seeking weight loss now use newer GLP-1 medicines instead.

What the science shows

Because it has been used in diabetes care since 2005, exenatide has one of the longest human safety records among GLP-1 medicines. In clinical studies its most common side effects were stomach-related, such as nausea, vomiting, and diarrhea, along with low blood sugar.

The catch

Exenatide is a prescription diabetes medicine, not a research peptide, and it is not approved for weight loss. Its label carries the FDA's most serious (boxed) warning because the long-acting form caused thyroid tumors in rats, and serious inflammation of the pancreas (pancreatitis) has been reported in people using GLP-1 medicines. As of 2026 the maker has stopped selling the long-acting brands Bydureon and Bydureon BCise and the FDA has withdrawn their approval, a business decision rather than a safety recall.

Reference summary

Exenatide was the first GLP-1 receptor agonist approved in the US and is one of the longest-running safety-evidence GLP-1s. pepSmart surfaces label-reference schedules only.

Regulatory and posture

Categories

GLP-1, Fat Loss

Aliases

Byetta, Bydureon BCise, Exendin-4 analog

Evidence posture

human

Regulatory status

FDA-approved exenatide label references exist for Byetta (twice-daily, first approved 2005) and the once-weekly extended-release Bydureon family. Both were approved as adjuncts to diet and exercise in adults with type 2 diabetes; they are not approved as weight-loss therapies. In a Federal Register notice published March 9, 2026, FDA withdrew approval of the long-acting Bydureon (NDA 022200) and Bydureon BCise (NDA 209210) applications at the applicant's request because the products are no longer marketed (a voluntary, non-safety withdrawal), so the long-acting brands are exiting the US market; confirm current availability of any specific exenatide product before relying on it.

Content review status

label verified

Related tools

• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• GLP-1 taper planner overview - Public overview of the Pro GLP-1 taper planner.
• Plateau analyzer overview - Public overview of the Pro plateau-pattern analyzer.